Compare Carnival Corp (CCL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Quest Diagnostics Inc — how do they compare? Carnival Corp trades at $27.08 (market cap $36.30B), while Quest Diagnostics Inc trades at $204.69 (market cap $22.80B). The key difference: Carnival Corp is the larger of the two by market cap, and Carnival Corp pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| CCL | DGX | |
|---|---|---|
Market Cap | $36.30B | $22.80B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $216.02 |
52-Week Low | $23.89 | $166.42 |
Enterprise Value | $60.22B | $28.82B |
Dividend Yield | 1.7% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.
The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
